Lu sur http://www.ncbi.nlm.nih.gov/pubmed/2617 ... t=Abstract
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.
Benatar M1, Mcdermott MP1, Sanders DB1, Wolfe GI1, Barohn RJ1, Nowak RJ1, Hehir M1, Juel V1, Katzberg H1, Tawil R1; Muscle Study Group (MSG).
Muscle Nerve. 2016 Mar;53(3):363-9. doi: 10.1002/mus.24769. Epub 2016 Jan 27.
Muscle Nerve 53: 363-369, 2016.
In this study we evaluated the safety, tolerability, and efficacy of prednisone in patients with ocular myasthenia gravis (OMG) concurrently treated with pyridostigmine.
This investigation was a randomized, double-blind, placebo-controlled trial. Participants whose symptoms failed to remit on pyridostigmine were randomized to receive placebo or prednisone, initiated at 10 mg every other day, and titrated to a maximum of 40 mg/day over 16 weeks. The primary outcome measure was treatment failure.
Fewer subjects were randomized than the 88 planned. Of the 11 randomized, 9 completed 16 weeks of double-blind therapy. Treatment failure incidence was 100% (95% CI 48%-100%) in the placebo group (n = 5) vs. 17% (95% CI 0%-64%) in the prednisone group, P = 0.02 (n = 6). Median time to sustained minimal manifestation status (MMS) was 14 weeks, requiring an average prednisone dose of 15 mg/day. Adverse events were infrequent and generally mild in both groups.
A strategy of low-dose prednisone with gradual escalation appears to be safe, well-tolerated, and effective in treating OMG
© 2015 Wiley Periodicals, Inc.